Kaletra (Lopinavir/Ritonavir)

The Latest

ABT-378/Ritonavir and Efavirenz for Salvage Therapy in Patients Multiply-Exposed to PIs

ABT-378/ritonavir and efavirenz for salvage therapy in patients multiply-exposed to PIs (TuPeB3196) Authored by N. Clumek, P.M. Girard, A. Telenti, J. Rockstroh, S. Becker, A. Lazzarin, S. Brun, E. Sun, X.U. Yi

Some of the most exciting data p...

By Judith Feinberg, M.D.

Kaletra™ (ABT-378/r) Application for Accelerated Approval

On June 1 Abbott Laboratories announced that it had filed a New Drug Application with the U.S. FDA for accelerated approval of its new protease inhibitor, new brand name Kaletra (pronunciation Kuh Lee Truh) (generic name lopinavir/ritonavir, most wid...

By AIDS Treatment News

Lopinavir: The Most Potent Protease Inhibitor

Unprecedented Anti-HIV Activity Efficacy in Treatment-naive Persons Efficacy in Treatment-experienced Persons Beyond Resistance Conclusion Selected Sources

In a season that will likely see few drug candidates appearing on the market, Abb...

By Nicholas Cheonis for San Francisco AIDS Foundation

ABT-378: A New Protease Inhibitor From Abbott

An oral presentation by Dr. Sham from Abbott laboratories (abstr #14) and a large series of posters (#206-213) presented the first look at ABT-378, a novel protease inhibitor. ABT-38 was designed to overcome some of the limitations of ritonavir, and ...

By Andrew T. Pavia, M.D.